GLUE — Monte Rosa Therapeutics Share News
0.000.00%
Last trade - 00:00- $947.83m
- $326.73m
- $123.67m
Brief: Monte Rosa Therapeutics Announces First Participants Dosed In MRT-6160 Phase 1 Study
Brief: Monte Rosa Therapeutics Q2 EPS USD -0.43
Brief: Monte Rosa Therapeutics Announces Leadership Team Promotions
U.S. STOCKS ON THE MOVE-CME Group, Meta, Coterra Energy
U.S. STOCKS ON THE MOVE-Canada Goose, Spire Global, Under Armour
Monte Rosa Therapeutics drops on $100 mln equity offering
Brief: Monte Rosa Therapeutics Announces Pricing Of $100 Mln Underwritten Public Offering
Brief: Monte Rosa Therapeutics Q1 Net Income USD -31.968 Million
Brief: Monte Rosa Therapeutics Announces Q4 And FY 2023 Financial Results
Brief: Monte Rosa Therapeutics Q4 EPS USD -0.58
Brief: Monte Rosa Therapeutics Announces Initiation Of Ind Enabling Studies For Mrt-8102
U.S. RESEARCH ROUNDUP-Avantor, HubSpot, Veeco Instruments
Brief: Monte Rosa Therapeutics Provides Corporate Update And Key Anticipated Milestones For 2024
Brief: Monte Rosa Therapeutics Q3 EPS USD -0.7
Brief: Monte Rosa Therapeutics Announces $25 Mln Registered Direct Offering
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Brief: Monte Rosa Therapeutics Q2 EPS USD -0.71
Brief: Monte Rosa Therapeutics Appoints Anthony Manning To Board Of Directors
Brief: Monte Rosa Therapeutics Advances Second Development Candidate, Mrt-6160, For Treating Autoimmune Diseases